Clinical Trials Browser

Interventional × Melanoma × spartalizumab × Clear all

NCT03958383 2026-06-03

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Phase 1/2 Terminated

8 enrolled 12 charts

Melanoma

NCT06425926 2026-03-27

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Phase 1/2 Recruiting

Melanoma

NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Phase 1 Active not recruiting

BreastDermatologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Phase 1 Recruiting

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Phase 1 Recruiting

Melanoma, Skin Neoplasms

NCT05751928 2025-07-08

NEO-MIMAJOR

Phase 3 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Phase 1 Completed

BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Phase 1 Terminated

DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03991130 2025-02-06

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Terminated

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT03009058 2024-11-25

MODULATE

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase 2 Terminated

4 enrolled 8 charts

Melanoma

NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase 2 Terminated

315 enrolled 73 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

NCT03301896 2024-06-20

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1 Terminated

Melanoma

NCT03484923 2024-06-18

PLATforM

Phase 2 Completed

196 enrolled 22 charts

Melanoma

NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Terminated

252 enrolled 67 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02658890 2023-08-28

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Phase 1/2 Completed

627 enrolled 59 charts

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Phase 1 Completed

Melanoma

NCT01176461 2023-01-18

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Phase 1 Completed

Melanoma

NCT02607813 2022-12-21

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Phase 1 Terminated

DermatologicGynecologic

Melanoma, Ovarian Neoplasms

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

319 enrolled 41 charts

BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1/2 Completed

490 enrolled 77 charts

DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

NCT02807844 2021-08-11

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

141 enrolled 58 charts

BreastDermatologicGastrointestinalGynecologic

Melanoma, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04928365 2021-06-16

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Phase 2 Unknown

Melanoma

NCT02112032 2021-05-05

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Phase 1 Completed

Melanoma

NCT04072900 2020-04-28

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Phase 1 Unknown

Melanoma, Neoplasm Metastasis

NCT03982134 2019-10-04

PDR001 + Panobinostat for Melanoma and NSCLC

Phase 1 Withdrawn

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma